Could Guillain–Barré syndrome be triggered by COVID‐19 vaccination?

Aldeeb, Maya; Okar, Lina; Mahmud, Safa S.; Adeli, Gholam

doi:10.1002/ccr3.5237

Cited by 10 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immediate onset pattern of GBS following vaccination is different from the observed pattern for Zoster vaccines [84]; their reported Zoster vaccine onset pattern is consistent with the development of autoimmune antibodies in contrast to the immediate onset Zoster vaccine records in VAERS (Figure 3). Note that autoantibodies are detected for some GBS patients post COVID-19 vaccination [14,85]; onset of GBS for multiple patients is consistent with the development of autoantibodies [9,[13][14][15]19,[22][23][24][25][26][27][28][29][30][31].…”

Section: Guillain-barré Syndrome (Gbs)mentioning

confidence: 84%

“…GBS has been associated with in uenza [4] and COVID-19 vaccinations [5]. GBS has been reported following Moderna [6][7][8][9][10], P zer BioNTech BNT162b2 [11][12][13][14][15][16][17][18][19], Oxford AstraZeneca ChAdOx1 day [15,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34], Johnson & Johnson/Janssen Ad26.CoV2.S [10,[35][36][37][38][39], Sinopharm [33,34], and Sputnik V [34,40] COVID-19 vaccines. Many GBS patients are expected as sporadic cases and should not be considered causal [41].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Ricke¹

2022

J Mod Biol Drug Discov

View full text Add to dashboard Cite

ObjectiveSome individuals (vaccinees) experience pain related adverse events following vaccinations. The majority of these pain related vaccination reactogenicity adverse events resolve within days. Rare adverse events like Bell's palsy and Guillain-Barré syndrome (GBS) have been associated with some vaccines. Herein, multiple working hypotheses are examined in the context of available characteristics of vaccinees and onset of these pain related adverse events post vaccination. MethodsThe Vaccine Adverse Event Reporting System (VAERS) database was datamined for pain associated vaccine adverse events data by vaccine, age, gender, dose, and onset post vaccination. Results for vaccines with the highest number of pain related adverse events were compared. ResultsFor the pain related adverse events examined, the highest number of adverse events are reported within 1 day, roughly half this number the second day, and roughly a quarter this number by the third day. The day of onset for these pain related adverse events approximates a power of two decay pattern for the rst three days. This same pattern is observed for all of the vaccines with the highest number of pain related adverse events. The consistency of these day of onset frequency patterns of examined adverse events following vaccinations for multiple unrelated vaccines enables the exclusion of speci c vaccine components and excipients as speci cally causative entities. ConclusionThe observed onset occurrences of examined pain associated adverse events are consistent with likely etiology relationship with innate immune responses to vaccinations for multiple vaccines including SARS-CoV-2 COVID-19, in uenza, and additional vaccines. Innate immune responses may be contributing to the initial etiology of Bell's palsy and GBS post SARS-CoV-2 mRNA and adenoviral vaccinations.

show abstract

Section: Guillain-barré Syndrome (Gbs)mentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Ricke¹

2022

J Mod Biol Drug Discov

View full text Add to dashboard Cite

show abstract

“…One paper which was eligible for inclusion was identified through the reference lists of the included papers. In total 71 articles have been included in the review [ 1 , 2 , 6 , 9 - 76 ]. Three of those papers provided relevant data regarding the prevalence and incidence of post COVID-19 vaccination GBS [ 9 - 11 ], while the others were mainly case reports or small case series comprising of a total of 138 patients with COVID-19 vaccine-related GBS.…”

Section: Reviewmentioning

confidence: 99%

“…GBS is a rare but serious immune-mediated disease characterized by damage to the peripheral and autonomic nervous system and is one of the known leading causes of flaccid paralysis worldwide [ 2 ], with an estimated annual median incidence of 11 persons per 1,000,000 population [ 3 ]. Although it is relatively rare, it may be life-threatening and debilitating.…”

Section: Introductionmentioning

confidence: 99%

Guillain-Barré Syndrome Induced by Vaccination Against COVID-19: A Systematic Review and Meta-Analysis

Ogunjimi¹,

Tsalamandris²,

Paladini³

et al. 2023

Cureus

View full text Add to dashboard Cite

Guillain-Barré syndrome (GBS) is a rare but serious immune-mediated neurological condition characterized by damage to the peripheral nervous system. Two-thirds of cases of GBS are diagnosed following infection; however, vaccination has also been linked to GBS pathogenesis. The aim of this systematic review and metaanalysis was to establish the prevalence of GBS following vaccination against the SARS-CoV-2 virus, which causes COVID-19, describe the clinical and neurophysiological characteristics, and identify potential determinants. A systematic review of the literature regarding post-vaccination GBS was conducted using the PubMed database. Seventy papers were included. The pooled prevalence of GBS after vaccination against COVID-19 per has been established to be 8.1 (95% CI 30-220) per 1,000,000 vaccinations. Vaccination with vector vaccines -but not mRNA -has been associated with an increased risk of GBS. More than 80% of the patients developed GBS within 21 days following the first dose of the vaccination. The interval between the vaccination and GBS was shorter in patients who were vaccinated with mRNA versus vector vaccines (9.7±6.7 days versus 14.2±6.6 days). Epidemiological findings regarding post-vaccination GBS revealed a higher prevalence in males and people between the ages of 40 and 60 years, with a mean age of 56.8±16.1 years. The most common type was the acute inflammatory demyelinating polyneuropathy type. Most cases responded well to treatment. In conclusion, vaccination against COVID-19 with vector vaccines seems to increase the risk of GBS. GBS occurring following vaccination does differ in characteristics from GBS during the pre-COVID-19 era.

show abstract

SARS‐CoV‐2 vaccinations can trigger polyradiculitis

Finsterer¹,

Almas

2022

Clinical Case Reports

View full text Add to dashboard Cite

Could Guillain–Barré syndrome be triggered by COVID‐19 vaccination?

Cited by 10 publications

References 4 publications

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Pain Adverse Events, Bell’s Palsy, and Guillain-Barré Syndrome Following Vaccination

Guillain-Barré Syndrome Induced by Vaccination Against COVID-19: A Systematic Review and Meta-Analysis

SARS‐CoV‐2 vaccinations can trigger polyradiculitis

Contact Info

Product

Resources

About